contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-herantis-pharma-soon-again-a-stronger-clinical-company

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Partnership Roche & Herantis Pharma might be a ”winning combo”…. https://x.com/ristopar/status/1998767454265422170?s=46

I asked Elon Musk Ai’s  opinion, is partnership Roche & Herantis Pharma potentiial and viable. Answer: First to Stop (or Cure) PD? Not Quite—But Game-Changers in the Works PD’s brutal—no cure, just symptom managers. “Stopping” progression is the holy grail for disease-modifiers, and both programs hype that potential, but neither’s there yet: • HER-096: Fresh off Phase 1b success (safe, brain-penetrant, stable symptoms), plus a clean 6-month tox study in Nov 2025. It’s positioned as a potential “first-in-class” to halt progression by hitting root causes, with full biomarkers due end-2025. Phase 2 efficacy readouts? Not till 2027-ish. Backed by MJFF and Parkinson’s UK, it’s promising but early. • Roche’s Prasinezumab: Further along in Phase III (starting late 2025/early 2026), with data showing motor slowdown in subsets. If it pans out, it could be the first approved modifier to slow PD—not cure, but a massive leap. Roche’s betting big, calling it a “revolution” in neurodegeneration. Neither’s a cure (reversing damage fully? Decades away, if ever). But prasinezumab might claim “first to slow” bragging rights sooner, while HER-096 could differentiate on repair. If they partnered, it’d be a powerhouse combo—synergistic mechanisms, shared trials?

Herantis’s Antti Vuolanto was at Life Science Night talking about his company.               Topics: 00:00 Herantis Pharma briefly 01:56 Parkinson’s Disease: High Unmet Need Driving Market Growth 07:29 HER-096 10:53 HER-096 Phase 1 Program 12:12 Partnering & Financing Goal 13:48 External Validation of HER-096 for Disease Modification in Parkinson’s 14:54 Q&A session

Tomorrow, Herantis will participate in Inderes’ company evening, which will include a company presentation and a Q&A session. Questions can be sent during the event in the chat or via the forum. Messages sent here by tomorrow morning will still be reached.

HER-096 development is built on 15 years of research and development work related to CDNF’s role in neurodegeneration both in the academia and in the industry.  This work has generated many important insights and data to help us understand how HER-096 works, and how cells and tissues respond to exposure to HER-096.                    Herantis Pharma              Herantis Pharma - How does HER-096 work in the body?    Innovative therapies for better lives

Note, latest timing info!  Herantis expects to report the Phase 1b biomarker data by mid-January 2026, in advance of the JP Morgan Healthcare Conference week in San Francisco, where the Company’s management will be available for meetings.  Herantis plans to initiate a Phase 2 clinical trial in 2026 to evaluate the efficacy, safety, and tolerability of HER-096 in people with Parkinson’s disease.

This link contains key information about an approved, commonly used medication for the “treatment” of Parkinson’s disease. Much seems to be based on guesswork regarding the mechanism of action and contraindications. Hopefully, Herantis Pharma’s HER-096 gets on the fast track.            organon.com              sinemet_pi.pdf

Herantis Pharma

Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– an engineered derivative of its previous lead drug CDNF that allows for non-invasive administration...

<div class="mfn-body"><p>Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– an engineered derivative of its previous lead drug CDNF that allows for non-invasive administration. We slightly raise our base case to SEK 24 per share (22) and expect Herantis to take the important step back into the clinic now in H1 2023.<br><a rel="nofollow noopener" href="https://backapp.redeye.se/articles/download-file/480a252a-1a93-31e8-bc05-1e00beb0ffc7"><br></a><a rel="nofollow noopener" href="https://www.redeye.se/research/870408/herantis-pharma-soon-again-a-stronger-clinical-company">Read more and download the Research Update.</a></p><p>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.</p><p>This is a press release from Redeye - Research Powered Investment Banking.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/7d94a7d8-e3b9-4f98-9fb7-fcf8c07e6fe6/herantis-pharma-soon-again-a-stronger-clinical-company.pdf" class="mfn-generated mfn-primary">Herantis Pharma - Soon again a (stronger) clinical company</a></p></div>